At the heart of this evolution lies the growing prominence of biologics contract manufacturing, a strategic partnership that is reshaping the way pharmaceutical companies approach their production ...

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site. Financing from OrbiMed, Novo Holdings, Jeito Capital, and others ...

CHMP has granted Eisai Europe and Biogen a positive opinion for the use of their monoclonal antibody therapy in treating early Alzheimer’s disease.

SEOUL, Jan. 14 (Yonhap) -- Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Tuesday it has received a contract manufacturing deal worth 2.07 trillion won (US$1.4 billion ...

One day after Samsung Biologics revealed in a regulatory filing that it had signed its largest contract in company history, the CDMO giant said it's considering the construction of a sixth ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products and could be used to respond to an emerging pandemic ...

The discussion took place on April 3, 11:00 a.m. – noon, innovation stage, #1281. One of the participants, Steve Perry of Catalent Biologics, spoke with Contract Pharma to share the company’s thoughts ...

To the growth of the global market. The Biologics Contract Development And Manufacturing Organization (CDMO) Market report forecasts market growth by revenue at global, regional & country levels ...

Continuous manufacturing and biologics production is the way forward in the wake of rising demand for personalized medicines among key players like Lonza and Catalent. The focus on cost efficiency ...